



Simplify the path to PrEP with CDC guideline–recommended testing

PrEP medications could benefit an estimated 1.2M people in the US, **but fewer than 36% of them are taking such prescriptions.**¹

Quest offers flexible, reliable testing for PrEP

Our HIV PrEP test offerings include all the most recent CDC guideline-recommended tests to determine clinical eligibility and to monitor patients while on PrEP. Test codes are now available to make testing simple and flexible to meet your patient's needs.

- ✔ **Flexible testing options** so you can choose the right test based on your patient's unique requirements
- ✔ **Billing and reimbursement challenges** are mitigated by our updated menu offering
- ✔ **Gender-inclusive testing language** designed to cater to all your patients, regardless of gender
- ✔ **Accessible testing options** with approximately 2,000 Patient Service Centers and in-office phlebotomists to help patients get the tests they need, when they need them

Eliminating cost barriers to PrEP testing and care

The USPSTF issued a grade A recommendation for prescribing PrEP for persons at increased risk of acquiring HIV.^{2,3} Accordingly, under the Affordable Care Act, many plans, including the ones below, are required to cover PrEP and associated lab testing without cost-sharing.⁴

- ✔ **Non-grandfathered private health insurance plans**
- ✔ **Medicaid expansion plans**
- ✔ **Traditional Medicaid plans^a**

Our tests are coded in alignment with these guidelines to help facilitate a smooth billing and reimbursement process for you and your patients.

PrEP could help reduce the risk of getting HIV

 From sex by about 99%⁴

 From injection drug use by at least 74%⁴

^aOptional for adults, depending on state policy; however, preventive services for children are often covered as part of the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit for children.

Identify patients eligible for PrEP therapy initiation or continuation



Updated CDC guidance states that **all sexually active adults and adolescents, and/or persons who inject drugs**, should receive information about PrEP, and its role in reducing the risk of acquiring HIV.⁵ PrEP is particularly recommended for patients who report behaviors or circumstances that place them at substantial risk of exposure and infection, including⁵

- HIV-positive sexual or injection partner
- Bacterial sexually transmitted infection in the past 6 months
- History of inconsistent or no condom use with sexual partner(s)

Patients must meet several conditions prior to beginning oral or injectable PrEP⁵

- Documented negative HIV Ab/Ag test result within 1 week before initially prescribing PrEP
- No signs/symptoms of acute HIV infection
- Estimated creatine clearance ≥ 30 ml/min^b
- No contraindicated medications

The updated CDC guidelines feature 2 testing algorithms that include confirmatory HIV testing as part of a baseline assessment for patients beginning or continuing PrEP.⁵



^b Only for patients who are considering daily oral PrEP use; not needed for patients who are considering injectable PrEP. Estimated creatine clearance (eCrCl) by Cockcroft Gault formula ≥ 60 ml/min for F/TDF use, ≥ 30 ml/min for F/TAF use.

Monitoring patients on PrEP

Prior to and while taking PrEP, laboratory testing is recommended.⁵ Updated guidance from the CDC recommends laboratory testing at various intervals to assess and confirm HIV-negative status and determine if patients are experiencing any negative side effects from the medication.⁵

Recommended schedule of lab tests for patients prescribed oral PrEP⁵

Test	Screening/baseline visit	3 months	6 months	12 months	When stopping PrEP
HIV	PrEP HIV-1/2 Antigen/Antibodies, 4th Generation, Reflex to Differentiation (TC 13595) ^d	PrEP HIV-1/2 Antigen and Antibodies, Fourth Generation, Screen and HIV-1 RNA (TC 13590)			PrEP HIV-1/2 Antigen/Antibodies, 4th Generation, Reflex to Differentiation (TC 13595) ^d
eCrCl	PrEP Creatinine (TC 13697)		PrEP Creatinine (TC 13697) If age ≥50 or eCrCl <90 ml/min at PrEP initiation	PrEP Creatinine (TC 13697) If age ≥50 or eCrCl <90 ml/min at PrEP initiation	PrEP Creatinine (TC 13697)
Syphilis	PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA (TC 13698)	PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA (TC 13698) ^e	PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA (TC 13698)		PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA (TC 13698) ^e
Chlamydia/gonorrhea	PrEP Chlamydia/ <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital (TC 13701)	PrEP Chlamydia/ <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital (TC 13701) ^e	PrEP Chlamydia/ <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital (TC 13701)		PrEP Chlamydia/ <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital (TC 13701) ^e
Lipid panel (F/TAF)	Recommended			Recommended	
Hepatitis B	PrEP HBV Triple Screen Panel with Reflexes (TC 13660)				
Hepatitis C	PrEP Hepatitis C Antibody with Reflex to HCV, RNA, PCR (TC 13667) ^f			PrEP Hepatitis C Antibody with Reflex to HCV, RNA, PCR (TC 13667) ^f	

^d Assess for acute HIV infection (see page 2).

^e Only for men who have sex with men and transgender women.

^f Only for men who have sex with men, transgender women, and persons who inject drugs.

Recommended schedule of lab tests for patients prescribed injectable cabotegravir (CAB) PrEP therapy⁵

Test	Initiation visit	1 month visit	Every 2 months	Every 4 months	Every 6 months	Every 12 months	When stopping CAB
HIV	PrEP HIV-1 RNA, Qualitative Real-Time PCR (TC 13600)	PrEP HIV-1 RNA, Qualitative Real-Time PCR (TC 13600)	PrEP HIV-1 RNA, Qualitative Real-Time PCR (TC 13600)	PrEP HIV-1 RNA, Qualitative Real-Time PCR (TC 13600)	PrEP HIV-1 RNA, Qualitative Real-Time PCR (TC 13600)	PrEP HIV-1 RNA, Qualitative Real-Time PCR (TC 13600)	PrEP HIV-1 RNA, Qualitative Real-Time PCR (TC 13600)
Syphilis	PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA (TC 13698)			PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA (TC 13698) ^e	PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA (TC 13698)	PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA (TC 13698)	PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA (TC 13698) ^e
Chlamydia/gonorrhea	PrEP Chlamydia/ <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital (TC 13701)			PrEP Chlamydia/ <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital (TC 13701) ^e	PrEP Chlamydia/ <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital (TC 13701)	PrEP Chlamydia/ <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital (TC 13701)	PrEP Chlamydia/ <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital (TC 13701) ^e

^e Only for men who have sex with men and transgender women.

A comprehensive range of CDC guideline–recommended PrEP testing

PrEP therapy is a proven intervention to help reduce the risk of HIV transmission.⁵ In alignment with CDC guidelines for PrEP monitoring, our portfolio includes baseline testing to determine eligibility for PrEP, and ongoing testing to continually monitor patients for HIV infection, STIs, and any adverse PrEP medication effects. Our portfolio of PrEP tests is the perfect compliment to your patient's PrEP journey.

- Right-sized with tests aligned to CDC guidelines for recommended testing
- Flexible to allow you to order tests based on the patient's presentation
- Clearly identified to facilitate easy, quick reimbursement and help minimize patient out-of-pocket expenses

Test code	CPT® code	Test name
13590	87389,87535	PrEP HIV-1/2 Antigen and Antibodies, Fourth Generation, Screen and HIV-1 RNA
13595	87389	PrEP HIV-1/2 Antigen/Antibodies, 4th Generation, Reflex to Differentiation
13600	87535	PrEP HIV-1 RNA, Qualitative Real-Time PCR
13670	87389	PrEP HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
13660	87340,86704,86317	PrEP HBV Triple Screen Panel with Reflexes Includes Hepatitis B Surface Antigen with Reflex Confirmation; Hepatitis B Core Antibody, Total, with Reflex to IgM; Hepatitis B Surface Antibody, Quantitative
13667	86803	PrEP Hepatitis C Antibody with Reflex to HCV, RNA, PCR
13698	86592	PrEP RPR (Diagnosis) with Reflex Titer and <i>Treponema pallidum</i> Antibody, IA
13701	87491,87591	PrEP Chlamydia/ <i>Neisseria gonorrhoeae</i> RNA, TMA, Urogenital
13697	82565	PrEP Creatinine
13696	84702	PrEP hCG, Total, Quantitative



Expanding access to PrEP is essential to close gaps in HIV care and bring an end to the HIV epidemic. **Visit [QuestHIVTesting.com](https://www.questdiagnostics.com/questhivtesting) to learn more** about how we can support your efforts to deliver essential HIV testing and prevention for your patients.

References:

1. Office of Infectious Disease and HIV/AIDS Policy, HHS. Ready, set, PrEP. [HIV.gov](https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/prep-program/). Updated March 18, 2022. Accessed October 5, 2023. <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/prep-program/> 2. CDC. HIV preventive services coverage. Updated May 5, 2020. Accessed March 7, 2024. <https://www.cdc.gov/nchhstp/highqualitycare/preventiveservices/hiv aids.html> 3. USPSTF. Preexposure prophylaxis to prevent acquisition of HIV. US Preventive Services Task Force recommendation statement. *JAMA*. 2023;330(8):736-745. doi:10.1001/jama.2023.14461 4. CDC. Pre-Exposure Prophylaxis (PrEP). Updated July 5, 2022. Accessed October 5, 2023. <https://www.cdc.gov/hiv/risk/prep/index.html> 5. US Public Health Service, CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2021 update – a clinical practice guideline. Accessed October 5, 2023. <https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf>

Test codes may vary by location. Please contact your local laboratory for more information.

The CPT® codes provided are based on American Medical Association guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

The updated guideline was developed by the CDC. It is provided for informational purposes only and is not intended as medical advice. A physician's test selection and interpretation, diagnosis, and patient management decisions should be based on his/ her education, clinical expertise, and assessment of the patient.

Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. SB12509 5/2024

